What Is Homeopathy?

1. "Like cures like" (similia similibus curantur) - a substance that causes symptoms in a healthy person can cure the same symptoms in a sick person. For example, onions (which cause watery eyes) might be used to treat allergic rhinitis.
2. Law of infinitesimals - the more diluted a remedy, the more potent it becomes. This directly contradicts conventional pharmacology, where dose-response relationships are foundational.

How Remedies Are Made

• Common dilutions are written as "30C" - meaning the substance was diluted 1:100 a total of 30 times.
• At 12C dilution, you have passed Avogadro's number (~6 × 10²³), meaning statistically not a single molecule of the original substance remains.
• Proponents invoke "water memory" - the idea that water retains an imprint of the substance - but this has no physical basis and has never been demonstrated under controlled conditions.

Common Uses

• Allergies and respiratory conditions
• Digestive issues
• Skin conditions
• Anxiety, fatigue, and chronic pain
• Childhood illnesses and teething
• Flu and infections (e.g., the product Oscillococcinum)

What the Evidence Says

• The 2015 Australian NHMRC systematic review (the most comprehensive to date) examined over 1,800 studies and found no good-quality evidence that homeopathy is effective for any health condition. A 2024-25 update from Australia's natural therapies review maintains this conclusion.
• The UK's NHS removed homeopathy from the National Health Service formulary in 2017, citing lack of evidence.
• The WHO has explicitly warned against using homeopathy in place of evidence-based treatments for serious diseases.
• A 2023 systematic review of meta-analyses (PMID 37805577) found that while some individual meta-analyses report positive outcomes, the overall quality of evidence is low and the effects are not reliably distinguishable from placebo.
• The landmark Shang et al. (2005) Lancet meta-analysis compared 110 homeopathy trials to 110 matched conventional medicine trials - after controlling for bias, evidence for specific effects of homeopathy was weak while evidence for conventional medicine was strong.

• Publication bias - positive results are more likely to be published
• Low-quality trial design - inadequate blinding, small sample sizes
• Regression to the mean - people often seek treatment when symptoms peak and naturally improve afterward
• Placebo effect - the therapeutic encounter itself (attentive listening, individualized attention) is beneficial

Scientific and Regulatory Status

Bottom Line

1. Indirect harm - delaying or replacing effective treatment for serious conditions
2. Financial harm - products can be expensive with no benefit beyond placebo
3. Direct harm - rare, but some products (especially those incorrectly labeled or containing actual substances) have caused poisoning, particularly in children

Heart Failure Drugs

The "Fantastic Four" - First-Line Disease-Modifying Therapy for HFrEF

1. ARNI - Angiotensin Receptor-Neprilysin Inhibitor

• Mechanism: Sacubitril inhibits neprilysin (which breaks down natriuretic peptides, adrenomedullin, bradykinin). Combined with valsartan (ARB) to block the RAAS, since neprilysin also degrades angiotensin II - preventing its buildup.
• Benefit: Reduces HF hospitalization, cardiovascular mortality, and all-cause mortality vs. enalapril (PARADIGM-HF trial). Also decreases LV size and improves symptoms.
• Target dose: 97/103 mg twice daily
• Key points:
  • Preferred over ACE inhibitor or ARB as first-line
  • Never combine with an ACE inhibitor (risk of angioedema - both raise bradykinin); require a 36-hour washout after stopping an ACE inhibitor before starting
  • Contraindicated if history of angioedema
  • Avoid if systolic BP <95 mmHg
  • Causes more hypotension but less renal dysfunction and hyperkalemia vs. ACE inhibitors

If sacubitril/valsartan is not tolerated or unavailable: use an ACE inhibitor (e.g., enalapril, lisinopril, ramipril) or ARB (e.g., candesartan, valsartan) as the alternative.

2. Beta-Blockers (β-Blockers)

• Mechanism: HF is driven by chronic sympathetic nervous system overactivation - causing vasoconstriction, sodium retention, myocyte hypertrophy, and apoptosis. Beta-blockers counteract these effects and reduce heart rate (which is an independent prognostic factor).
• Benefit: Improves LV systolic function, reduces hospital admissions, and strikingly improves survival when added to ARNI/ACEi/ARB + MRA + SGLT2i.
• Recommended for ALL patients with symptomatic systolic dysfunction, regardless of etiology or severity.
• Key points: Must be started at low dose and slowly up-titrated (e.g., carvedilol 3.125 mg BD → target 25 mg BD). Do not start during acute decompensation.
• Target dose varies: bisoprolol 10 mg/day, carvedilol 25-50 mg BD, metoprolol succinate 200 mg/day.

3. Mineralocorticoid Receptor Antagonists (MRAs)

• Mechanism: Aldosterone promotes sodium retention, potassium/magnesium loss, myocardial fibrosis, and cardiac remodeling. MRAs block aldosterone at its receptor.
• Benefit: Added to ACEi/ARB + beta-blocker, MRAs increase survival, reduce hospital admissions, and improve NYHA class in NYHA II-IV HFrEF.
• Eplerenone is also indicated post-MI with LV systolic dysfunction.
• Doses:
  • Spironolactone: start 25 mg once daily (or alternate days) → target 25-50 mg/day
  • Eplerenone: start 25 mg once daily → target 50 mg/day
• Key cautions:
  • Hyperkalemia (K+ >5.0 mmol/L - caution; K+ >5.5 - reduce/stop)
  • Significant renal dysfunction (creatinine >2.5 mg/dL - avoid)
  • Monitor electrolytes at 1, 4, 8, 12 weeks then 6-monthly
  • Spironolactone causes gynecomastia in men (eplerenone does not)

4. SGLT2 Inhibitors

• Mechanism: Inhibit SGLT2 in renal proximal tubule → glucosuria + natriuresis + osmotic diuresis. Additional possible mechanisms include reduced preload/afterload, myocardial metabolic effects, and mitochondrial protection.
• Benefit: When added to ARNI + beta-blocker + MRA, SGLT2 inhibitors reduce LV size, improve ejection fraction, reduce HF hospitalizations, and prolong survival - regardless of diabetes status (DAPA-HF, EMPEROR-Reduced trials).
• Dose: Dapagliflozin 10 mg once daily; Empagliflozin 10 mg once daily (no up-titration required)
• Contraindications: Previous diabetic ketoacidosis, eGFR <20 mL/min/1.73m²
• Cautions: Genital fungal infections (5-10%), ketoacidosis risk with insulin or low carbohydrate diet; hold 3 days before elective surgery.
• Also slow the rate of eGFR decline (renoprotective) and mitigate MRA-induced hyperkalemia.

Diuretics - Symptom Relief (Not Disease-Modifying)

• Used for relief of congestion (dyspnea, edema, orthopnea) but do not reduce mortality on their own.
• Loop diuretics (furosemide) are preferred for moderate-severe HF; thiazides for mild HF.
• In severe/resistant edema, combination of a loop diuretic + thiazide (e.g., metolazone) acts synergistically by blocking different nephron segments.
• IV loop diuretics (bolus or infusion) for acute decompensation.
• Monitor electrolytes and renal function closely.
• Dose timing can be adjusted for patient lifestyle (effect is prompt and short-lived).

Second-Line / Selected Patients

HFpEF (LVEF ≥50%)

• SGLT2 inhibitors (dapagliflozin, empagliflozin) - now shown to reduce HF hospitalizations in HFpEF (EMPEROR-Preserved, DELIVER trials)
• Diuretics - for congestion relief
• Finerenone - showed benefit in HFpEF in the FINEARTS-HF trial (2024)
• GLP-1 receptor agonists (semaglutide) - a 2025 systematic review (PMID 39993464) shows benefit in HFpEF/HFmrEF, improving quality of life and reducing HF events, especially in patients with obesity
• ARBs/ACEi, beta-blockers: used for comorbidities (hypertension, AF, CAD) but do not have a proven mortality benefit in isolated HFpEF

Acute Decompensated Heart Failure (ADHF)

Summary: HFrEF Evidence Pyramid

Tier 1 (Mortality benefit): ARNI > ACEi/ARB + Beta-blocker + MRA + SGLT2i
Tier 2 (Hospitalization/QoL): Diuretics, ivabradine, hydralazine-nitrate, vericiguat
Tier 3 (Selected uses): Digoxin, amiodarone (AF), anticoagulation (AF/thrombus)